Health ❯ Clinical Trials

Drug Development

Regulatory Approval Cancer Treatments FDA Approval Regulatory Affairs Phase 3 Trials Eli Lilly Combination Therapy Oncology Inhibitors Therapeutic Evaluation

Daraxonrasib Nearly Doubles Survival in Pancreatic Cancer Trial

The FDA fast-tracked review to open expanded access for some patients.

Oral GLP-1 Weight-Loss Pills Curb Hedonic Eating by Hitting Deep-Brain Circuit in Mice

Avalo Therapeutics Reports Positive Phase 2 HS Results, Prices $375 Million Offering

FDA Approves Filspari to Reduce Proteinuria in FSGS Patients Without Nephrotic Syndrome

Cancer Study Maps Brain Metastasis Switch and Identifies Ibudilast as a Repurposing Candidate

Gilead to Acquire Arcellx for Up to $7.8 Billion to Gain Full Control of CAR-T Anito-Cel

Polilaminina Enters Anvisa-Approved Phase 1 as Off-Protocol Use Expands and Scientists Urge Caution

p‑Tau217 Blood Tests Boost Alzheimer’s Diagnosis and Predict Onset Within a Few Years

Hypoxia Turns Red Blood Cells Into Glucose Sinks, Pointing to New Diabetes Therapies

Low-Dose THC Paired With Celecoxib Improves Cognition and Alzheimer’s Pathology in Mice

Novo Nordisk Files for 7.2 mg Wegovy Dose After Stronger Weight-Loss Results

Immune Cell Stress Switch Implicated in Chemo Neuropathy, With Existing Inhibitors Poised for Tests

Merck’s Oral PCSK9 Pill Matches Injectables in Phase 3, Setting Up 2026 FDA Bid

UC San Diego AI Identifies PRKAB1 Target to Reprogram Colon Cancer Stem Cells

Amivantamab ‘Smart Jab’ Shows 76% Disease Control in Advanced Head and Neck Cancer

Blocking C5aR1 Preserves Memory in Mouse Brain Radiotherapy Without Undermining Tumor Control

NRG Therapeutics Raises £50M to Advance Mitochondrial Neurodegeneration Drug Into the Clinic

Kidney Organoids Reveal NFκB‑Linked AAV2 Toxicity, With Bardoxolone Methyl Mitigating Damage

Agg-CLNP Nanotherapy Delays Rheumatoid Arthritis Onset and Tames Flares in Preclinical Models

Hormone-Free Pill YCT-529 Passes Phase 1 Safety Trial in Healthy Men